Member Info for Silverblade

Disappointing retrace. At this price company should consider restarting its buyback programme - although we are probably in a closed period with results due in less than a month. SB

It's possible. Income plays like GCP are closely linked to UK 10 year gilt yield - and that has risen sharply over last two weeks which increases yield expectation here back towards 9.5/10% territory. SB

Looks like our pals in the US are bailing. Wonder what news awaits us in the morning…..SB

Looking a bit ominous here now - perhaps the reason there was no FY update. SB

Not for the first time (I think) GCP goes ex-divi the day BOE announces interest rate decision. Probably co-incidence - but helps when rate cuts are announced. In theory GCP should benefit both from lower interest rates via reduction on gilt yields/discount rates; and sticky inflation where investments benefit from linkage. Looks like supported living sale is getting closer - and with that all debt will be paid off with a chunk of cash in the bank. SB

Surprised the market is punishing GCP after what has been a decent upwards period - although still a NAV discount shambles. Net debt down to £10m - although goodness knows what on earth was going on with regard to the solar RO claim - at least it went in their favour. Ex divi tomorrow so expect further falls in the morning. Disappointing as I was hoping to see price consolidate in low 80's after recent broker target (90p). SB

Paul H looks like he is having a cosy fireside chat which is his style - ineffective to say the least. IMO - given recent bomb scare events - there should be a higher level of interrogation on trading performance, budgets, KPI's which can be tracked to measure actual performance - rather then $900m, $300m addressable markets which are meaningless in the present. To say the fundraise only takes them into H2 2026 is worrying - implies further cash needed in 9 months. 2 more sales team members - is that it? Is that the current ambition? Sales in Q2 hardly grew at all - why? They need to sell c.3000 tutivia tests a year to breakeven (accept this does not take into account PTRA Thermo payments but they appear to be on hold). Current year appears to be targeting 1200 tests - so they need a plan to double this and then some. Fail - and where on earth is next years fundraise priced at. Sounding knowledgeable on product is one thing - running and growing a viable commercial business is where the focus needs to be. SB

Would have preferred to see some growth in H1 v 2024 - but they expect to hit £53m FY so perhaps starting to move. Must be generating c.£800k a month cash - adds to growing cash pile - £20m+ end of year. Get some deals and it could be a decent second half. Looks like market is starting to believe they won’t screw it up again…SB

Another exciting pharma services project which adds to the virtually non existent current pharma business revenue……Meanwhile the lack of a trading update leads to speculation as to why there has been no update to the downside….SB

Was thinking the same myself oogle. Let’s see if they can show some actual trading growth for a nice change. Same goes for Renx. Bit worrying no TU for full year has been issued. SB

It will be interesting to see what happens on Thursday. Good that the placing was oversubscribed, bad that even more shares have been issued than this mornings RNS. Now looking at 1.5b shares assuming retail gets taken up. At 0.5p that's a £7.5m market cap which will come under pressure. I don't think we are looking at 0.1p but 0.5p will be hard to hold imo. A lot now depends on the trading update - although we now know H1 revenue - c$1.6m. Delayed test revenue could help a bit. I have purchased today - either that or I write off my entire previous investment. Not comfortable with my actions whatsoever. £55k from the board isn't exactly setting the world on fire either. SB

Reread the RNS - the 299 tests in Q2 were reported. SB

This appeared in the LSE note “Orders rose further in the second quarter, with 299 tests recorded.” It was not in the RNS. So there goes the 68% growth. Ties back to the $3.2m 2025 revenue prediction. No wonder they had to raise at 0.5p. SB

To carry this out without a half year trading update just seems completely inappropriate. IIs must have asked the question. To get back to 1p a share will require the market cap to hit £13m - 6 times where we are today. Conversely if market cap stays at current level it’s trading in the 0.1/0.2p range. Shocking. SB

No update on Q2. £5.5m to last another 10 months. 1.35b shares. Market cap of £2m. Legendary stuff. SB

…nears profitability?! Have I missed something….the business is days from administration. Expect some type of an update in the morning either way. SB

There is no doubt there is a considerable target market for the Tutivia test - and other tests do not appear to provide the same level of accuracy in relation to transplant rejection so vrci have a leader in its field. And the clarava product appears to be well received hence the Thermo fisher deal. So in terms of technology - the company has some IP (licenced via its deal with Mount Sinai of course). In relation to the timing of reimbursement point - that is a historic issue which has now been dealt with Medicare coverage. To say the board are not responsible for progressing a timely HMRC EIS/VCT application having used one 18 months ago highlights the problem here - if the board are not responsible for sorting out their financial future then who is? Only this time around, instead of having $2.5m in the bank in early 2024 it has been left to the point where cash is about to run out - reducing powers of negotiation with anyone who is interested in a punt here. II's who put money in are going to need a lot of convincing there is a business plan in place - and further evidence on revenue predictability. And that has led to a situation where any fund raise will likely wipe out existing equity holders. So even if they were to succeed - where does that leave existing investors - holding 10/20% of the company at best? It raises a huge question for PI's here - are you willing to pump more money into a placing or purchase shares on the open market to try and retain your current % shareholding? If not, you have answered your own question on whether the business has a future. Can the current management team be trusted to deliver? SB

CEO was in charge at Lunglife as well Nova888 - also now cancelled. And for this the CEO gets paid $400k a year without a single share in the company. SB

Looking like a tragic end to proceedings here. Shambles at the end. No wonder investors shy away from AIM. SB

Can't disagree with your observations Stuartrm - its been quite a source of frustration over the years where the market is looking for 'numbers' and we are instead offered 'partnerships'. What is clear is the need to continue growing the primary care physician network - and this is another step in the right direction. What is not clear - and this is an area which requires improvement - is the statements made by the company are not consistent. Sometimes they refer to large scale groups (ie 700,000 today) which includes diabetes/ckd patients; sometimes its specific patient numbers who will receive the test (2,000 announced back in June); sometimes its onboarding primary care GP practices. All useful - but there should be more consistent messaging so we can understand key performance metrics. And as you point out - how does this align with the 2026; 2027 revenue targets. And what about 2025 - has it been achieved. I can understand caution is being exercised given historic updates and poor market reaction - but these partnership updates come and go with little impact on proceedings apart from to generate a bit of chat here to try and eke out what positivity remains in the companies future! Also noted that the company changed its NOMAD today - perhaps SP Angel have been tasked with reinvigorating its investor base. SB